secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rani Therapeutics Holdings, Inc. (RANI)
CIK:        0001856725
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070344
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rani Therapeutics Q1 net loss $12.7M, cash $15.9M; RT-114 Phase 1 mid-2025
--------------------------------------------------------------------------

- Net loss was $12.7M for Q1 2025 ($14.8M in Q1 2024); cash, equivalents and marketable securities fell to $15.9M from $27.6M at year-end.
- Preclinical data show RT-114 (oral bispecific GLP-1/GLP-2 agonist) bioequivalent to subcutaneous PG-102 with 111% relative bioavailability.
- Preclinical data also demonstrate oral semaglutide via RaniPill (RT-116) comparable to subcutaneous in bioavailability, PK, and weight loss.
- Phase 1 clinical trial for RT-114 treating obesity expected to begin mid-2025.
- R&D expenses decreased to $6.6M and G&A to $5.6M; contract revenue was $0.2M from evaluation services.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/0000950170-25-070344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1856725/000095017025070344/rani-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer